Are you Dr. Luyun?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
611 W Park St
Oncologyhematology
Urbana, IL 61801Phone+1 217-383-6636Fax+1 217-383-3466
Summary
- Dr. Ronnie Luyun, MD is an oncologist in Urbana, Illinois. He is currently licensed to practice medicine in Illinois and New York. He is affiliated with Samaritan Hospital - Main Campus and St. Peter's Hospital.
Education & Training
- NYU Grossman Long Island School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2002
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1996 - 1999
- Northwestern University The Feinberg School of MedicineClass of 1996
Certifications & Licensure
- NY State Medical License 1999 - 2026
- IL State Medical License 1996 - 2017
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
- Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
- Join now to see all
Publications & Presentations
PubMed
- 139 citationsA placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).Aminah Jatoi, Howard L. Ritter, Amylou C. Dueck, Phuong L. Nguyen, Daniel A. Nikcevich
Lung Cancer. 2010-05-01 - 37 citationsBrief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG ...Thanyanan Reungwetwattana, Julian R. Molina, Sumithra J. Mandrekar, Katie Allen-Ziegler, Kendrith M. Rowland
Journal of Thoracic Oncology. 2012-05-01 - 408 citationsPhase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaThomas E. Witzig, Susan Geyer, Irene M. Ghobrial, David J. Inwards, Rafael Fonseca
Journal of Clinical Oncology. 2005-08-10